A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

Abstract A02: Imprime PGG modulates the myeloid component of the tumor microenvironment to coordinate an antitumor immune response

(2016) Kathryn Fraser et al.   CANCER RESEARCH

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

(2016) C. E. Halstenson et al.   INVESTIGATIONAL NEW DRUGS

Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity

(2016) Steven M. Leonardo et al.   Cancer Immunology Research

Abstract B019: Imprime PGG, a soluble β-glucan, binds to and activates dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production

(2016) Ross B. Fulton et al.   Cancer Immunology Research

Abstract 5034: Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity

(2015) Steven M. Leonardo et al.   CANCER RESEARCH

Abstract LB-225: Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T-cell expansion

(2015) Anissa SH Chan et al.   CANCER RESEARCH

Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells

(2015) Nandita Bose et al.   CANCER RESEARCH

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

(2014) B. Besse et al.   ANNALS OF ONCOLOGY

Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype

(2014) Anissa SH Chan et al.   Journal for ImmunoTherapy of Cancer

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent

(2013) Nandita Bose et al.   Frontiers in Immunology

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) S. Peters et al.   ANNALS OF ONCOLOGY

Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived  -glucans

(2011) C. Qi et al.   BLOOD

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2011) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Yeast-derived β-glucan in Conjunction With Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models

(2009) Wangjian Zhong et al.   JOURNAL OF IMMUNOTHERAPY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Yeast-Derived  -Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models

(2008) C. Salvador et al.   CLINICAL CANCER RESEARCH